Search Results
Mar 09, 2026, 17:31 ET Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
obscure Notch ligand into a key oncology biomarker, impacting Small Cell Lung Cancer (SCLC), NETs, NEC, including Neuroendocrine Prostate Cancer (NEPC) and Extra-pulmonary NEC (EP-NEC), and Large cell Neuroendocrine Lung Carcinoma (LCNEC). Several companies have advanced gene therapies
More news about: DelveInsight Business Research, LLP
Mar 09, 2026, 08:30 ET American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Mar 09, 2026, 08:30 ET Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Mar 09, 2026, 07:30 ET ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
Authority (SFDA) recently approved ANKTIVA in combination with checkpoint inhibitors for patients with second-line and later metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after standard therapies, including checkpoint inhibitor treatment. In this setting, multiple randomized
More news about: ImmunityBio
Mar 09, 2026, 07:29 ET Rosewood Hotel Group Introduces Global Gender-Neutral Parental Leave Standard of 16 Weeks Fully Paid Leave for Associates Worldwide
reinforcing the Group's commitment to inclusion and equitable opportunity across regions and cultures.Keno Lung, Senior Vice President, Talent and Culture, Global, added: "Our associates are the heart of everything we do. Across hospitality, parenting
More news about: Rosewood Hotel Group
Mar 09, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy agent and
More news about: IDEAYA Biosciences, Inc.
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).The open-label, multi-center Phase Ⅱ clinical study is
More news about: Leads Biolabs
Mar 07, 2026, 10:16 ET U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China
March 7, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China.
More news about: Jiahui International Hospital
Mar 06, 2026, 23:20 ET U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China
March 6, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China.
More news about: Jiahui International Hospital
Mar 06, 2026, 07:00 ET Kedrion Activates Nationwide Distribution Network for QIVIGY® in the U.S.
high doses or rapid infusion.Hemolysis can develop subsequent to IGIV treatment. Monitor patients for hemolysis.Transfusion-related acute lung injury: Monitor patients for pulmonary adverse reactions.Transmissible infectious agents: QIVIGY is made from human plasma and may carry a risk
More news about: Kedrion Biopharma
Mar 06, 2026, 05:53 ET Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
multiple-ascending-dose (MAD) cohorts, designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adults.Kuo-Lung Huang, Chairman of TaiGen Biotechnology, said, "ISM4808 is an important milestone in TaiGen's drug development strategy. Within 3 months of in-licensing
More news about: Insilico Medicine
Mar 06, 2026, 04:20 ET Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.
Mar 05, 2026, 22:51 ET /C O R R E C T I O N -- Mercy Medical Center/
variety of cancers, as the hospital has earned High Performing honors from U.S. News & World Report in colon cancer, gynecologic cancer, and lung cancer surgery, and the Women's Choice Award's "America's Best for Cancer Care" and "America's Best for Comprehensive Breast Care" honors.Castle
More news about: Mercy Medical Center
Mar 05, 2026, 17:31 ET Global Companion Diagnostics Market to Register Immense Growth at a CAGR of ~12% by 2032 | DelveInsight
Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and OthersCompanion Diagnostics Market Segmentation By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, and OthersCompanion Diagnostics Market Segmentation By End-User: Hospitals, Diagnostic Labs,
More news about: DelveInsight Business Research, LLP
Mar 05, 2026, 11:23 ET Pulmonary Fibrosis Foundation expands national care network, strengthening access to expert lung disease care
Florida, Jacksonville, Fla.Montefiore's Advanced Pulmonary Failure and Lung Transplant Program, New York, N.Y.Mount Sinai Respiratory Institute, New York, N.Y.Ochsner Advanced Lung Disease Clinic, Kenner, La.St. Luke's University Health Network,
More news about: The Pulmonary Fibrosis Foundation
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
KIMMTRAK sales for full-year 2025, a 29% increase year over year. The ImmTAC platform is advancing clinical programs across melanoma, non-small cell lung cancer, and additional solid tumor indications."With $400 million in KIMMTRAK sales and a diverse clinical portfolio, Immunocore had a
More news about: Equity Insider
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
Lead mRNA program targeting an ultra-rare lung fibrosis and lead ASO program for ultra-rare central nervous system disorderCollaboration unveiled at the Personalized Medicine World ConferenceSAN FRANCISCO,
More news about: Therna Biosciences
Mar 05, 2026, 07:00 ET CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
Mar 05, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Mar 05, 2026, 03:03 ET Sectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging
https://news.cision.com/sectra/i/radiologist-reading-lung-x-ray-in-sectra-s-solution,c3516585Radiologist reading lung X-ray in Sectra's solution
More news about: Sectra
Mar 04, 2026, 17:31 ET Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight
said it had been granted orphan drug status by the European Medicines Agency for LTI-03, its leading investigational therapy designed to help maintain lung function in people with idiopathic pulmonary fibrosis.What are Orphan Drugs?Orphan drugs are medicines developed to diagnose,
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 10:00 ET Airiver Medical Granted FDA's Breakthrough Device Designation for Pulmonary Drug Coated Balloon to Treat Central Airway Stenosis; First Patient Treated in Clinical Trial
trial."Central airway stenosis, otherwise defined as airway narrowing, is often associated with prolonged intubation, tracheostomy, stenting, tuberculosis or lung transplant. There are approximately 100,000 tracheo-bronchial stenting and dilation procedures performed annually in the United States.The Airiver
More news about: Airiver Medical
Mar 04, 2026, 09:00 ET Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 2026
Repeated evaluation of AI for lung nodule detection in chest radiographs: version-to-version evaluation in a multicentre study
More news about: Lunit
Mar 04, 2026, 07:18 ET Brayton Purcell LLP Highlights New National InvestigateTV Report Exposing the Severe Health Consequences of Crystalline Silica Artificial Stone
crisis faced by California countertop fabrication worker Rodolfo Figueroa, whose decades of cutting artificial stone resulted in catastrophic lung damage.
More news about: Brayton Purcell LLP
Mar 04, 2026, 07:05 ET Allegheny Health Network's Cardiovascular Institute Achieves Elite National Ratings for Cardiac Surgery Excellence
surgeons, researchers, and allied healthcare professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society's mission is to enhance the ability of cardiothoracic surgeons to
More news about: Allegheny Health Network